A Phase 2, Multicenter, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
Latest Information Update: 03 Mar 2026
At a glance
- Drugs Hemopexin (Primary)
- Indications Sickle cell anaemia; Vaso-occlusive crisis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors CSL Behring
Most Recent Events
- 25 Feb 2026 Status changed from active, no longer recruiting to recruiting.
- 13 Jan 2026 Planned End Date changed from 4 Apr 2028 to 7 Aug 2027.
- 13 Jan 2026 Planned primary completion date changed from 4 Apr 2028 to 7 Aug 2027.